Kailera Therapeutics is trading 4.01% up at $18.66 as investors continue digesting its August 12, 2026 second-quarter report and business updates.
- Reported a $111.31 million quarterly net loss and highlighted $1.17 billion in cash.
- Plans to advance its oral obesity pipeline toward global pivotal trials.
- No separate August 17, 2026 announcement or major market catalyst was identified; the gain appears primarily company-related, while broader indexes were mixed during the session.